The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells

Masashi Shin, Kou Matsuo, Takeyuki Tada, Hidefumi Fukushima, Hiroyuki Furuta, Satoru Ozeki, Tomoko Kadowaki, Kenji Yamamoto, Masato Okamoto, Eijiro Jimi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Oral squamous cell carcinomas (OSCCs) are malignant tumors that frequently invade the maxilla and mandibular bone. However, the molecular mechanisms underlying bone invasion by OSCC are unclear. Recent studies showed that receptor activator of nuclear factor κB (RANK) was expressed not only in osteoclast precursors but also in tumor cells. Therefore, we examined whether RANK ligand (RANKL)/RANK signaling regulates bone invasion by OSCC cells in vivo and in vitro. We first injected human OSCC B88 cells into the masseter region of nude mice. Mice were treated for 3 weeks with osteoprotegerin (OPG), the decoy receptor for RANKL. Treatment with OPG decreased bone invasion by B88 cells, reduced the number of osteoclasts and increased B88 cell apoptosis. However, OPG did not affect apoptosis and proliferation in B88 cells in vitro, suggesting that the effects of OPG on apoptosis in B88 cells are restricted in a bone environment. RANK was expressed in the B88 cells and in OSCC cells from patients. RANKL induced NF-κB activation and extracellular signal-regulated kinase phosphorylation in B88 cells and enhanced B88 cell migration in a modified chemotaxis chamber equipped with a gelatin-coated filter. OPG inhibited RANKL-induced NF-κB activation, extracellular signal-regulated kinase phosphorylation and cell migration. Our data clearly indicate that RANKL/RANK inhibition suppresses bone invasion by inhibiting osteoclastogenesis and cancer cell migration and by inducing apoptosis of cancer cells via indirect anticancer action in vivo.

Original languageEnglish
Pages (from-to)1634-1640
Number of pages7
JournalCarcinogenesis
Volume32
Issue number11
DOIs
Publication statusPublished - Nov 1 2011

Fingerprint

RANK Ligand
Osteoprotegerin
Squamous Cell Carcinoma
Bone and Bones
Apoptosis
Cell Movement
Extracellular Signal-Regulated MAP Kinases
Osteoclasts
Neoplasms
Phosphorylation
Inhibition (Psychology)
Maxilla
Chemotaxis
Gelatin
Cytoplasmic and Nuclear Receptors
Osteogenesis
Nude Mice
Cell Count

All Science Journal Classification (ASJC) codes

  • Cancer Research

Cite this

The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells. / Shin, Masashi; Matsuo, Kou; Tada, Takeyuki; Fukushima, Hidefumi; Furuta, Hiroyuki; Ozeki, Satoru; Kadowaki, Tomoko; Yamamoto, Kenji; Okamoto, Masato; Jimi, Eijiro.

In: Carcinogenesis, Vol. 32, No. 11, 01.11.2011, p. 1634-1640.

Research output: Contribution to journalArticle

Shin, M, Matsuo, K, Tada, T, Fukushima, H, Furuta, H, Ozeki, S, Kadowaki, T, Yamamoto, K, Okamoto, M & Jimi, E 2011, 'The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells', Carcinogenesis, vol. 32, no. 11, pp. 1634-1640. https://doi.org/10.1093/carcin/bgr198
Shin, Masashi ; Matsuo, Kou ; Tada, Takeyuki ; Fukushima, Hidefumi ; Furuta, Hiroyuki ; Ozeki, Satoru ; Kadowaki, Tomoko ; Yamamoto, Kenji ; Okamoto, Masato ; Jimi, Eijiro. / The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells. In: Carcinogenesis. 2011 ; Vol. 32, No. 11. pp. 1634-1640.
@article{b78894e6d75a4ac99c8f15f2fc277c57,
title = "The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells",
abstract = "Oral squamous cell carcinomas (OSCCs) are malignant tumors that frequently invade the maxilla and mandibular bone. However, the molecular mechanisms underlying bone invasion by OSCC are unclear. Recent studies showed that receptor activator of nuclear factor κB (RANK) was expressed not only in osteoclast precursors but also in tumor cells. Therefore, we examined whether RANK ligand (RANKL)/RANK signaling regulates bone invasion by OSCC cells in vivo and in vitro. We first injected human OSCC B88 cells into the masseter region of nude mice. Mice were treated for 3 weeks with osteoprotegerin (OPG), the decoy receptor for RANKL. Treatment with OPG decreased bone invasion by B88 cells, reduced the number of osteoclasts and increased B88 cell apoptosis. However, OPG did not affect apoptosis and proliferation in B88 cells in vitro, suggesting that the effects of OPG on apoptosis in B88 cells are restricted in a bone environment. RANK was expressed in the B88 cells and in OSCC cells from patients. RANKL induced NF-κB activation and extracellular signal-regulated kinase phosphorylation in B88 cells and enhanced B88 cell migration in a modified chemotaxis chamber equipped with a gelatin-coated filter. OPG inhibited RANKL-induced NF-κB activation, extracellular signal-regulated kinase phosphorylation and cell migration. Our data clearly indicate that RANKL/RANK inhibition suppresses bone invasion by inhibiting osteoclastogenesis and cancer cell migration and by inducing apoptosis of cancer cells via indirect anticancer action in vivo.",
author = "Masashi Shin and Kou Matsuo and Takeyuki Tada and Hidefumi Fukushima and Hiroyuki Furuta and Satoru Ozeki and Tomoko Kadowaki and Kenji Yamamoto and Masato Okamoto and Eijiro Jimi",
year = "2011",
month = "11",
day = "1",
doi = "10.1093/carcin/bgr198",
language = "English",
volume = "32",
pages = "1634--1640",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells

AU - Shin, Masashi

AU - Matsuo, Kou

AU - Tada, Takeyuki

AU - Fukushima, Hidefumi

AU - Furuta, Hiroyuki

AU - Ozeki, Satoru

AU - Kadowaki, Tomoko

AU - Yamamoto, Kenji

AU - Okamoto, Masato

AU - Jimi, Eijiro

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Oral squamous cell carcinomas (OSCCs) are malignant tumors that frequently invade the maxilla and mandibular bone. However, the molecular mechanisms underlying bone invasion by OSCC are unclear. Recent studies showed that receptor activator of nuclear factor κB (RANK) was expressed not only in osteoclast precursors but also in tumor cells. Therefore, we examined whether RANK ligand (RANKL)/RANK signaling regulates bone invasion by OSCC cells in vivo and in vitro. We first injected human OSCC B88 cells into the masseter region of nude mice. Mice were treated for 3 weeks with osteoprotegerin (OPG), the decoy receptor for RANKL. Treatment with OPG decreased bone invasion by B88 cells, reduced the number of osteoclasts and increased B88 cell apoptosis. However, OPG did not affect apoptosis and proliferation in B88 cells in vitro, suggesting that the effects of OPG on apoptosis in B88 cells are restricted in a bone environment. RANK was expressed in the B88 cells and in OSCC cells from patients. RANKL induced NF-κB activation and extracellular signal-regulated kinase phosphorylation in B88 cells and enhanced B88 cell migration in a modified chemotaxis chamber equipped with a gelatin-coated filter. OPG inhibited RANKL-induced NF-κB activation, extracellular signal-regulated kinase phosphorylation and cell migration. Our data clearly indicate that RANKL/RANK inhibition suppresses bone invasion by inhibiting osteoclastogenesis and cancer cell migration and by inducing apoptosis of cancer cells via indirect anticancer action in vivo.

AB - Oral squamous cell carcinomas (OSCCs) are malignant tumors that frequently invade the maxilla and mandibular bone. However, the molecular mechanisms underlying bone invasion by OSCC are unclear. Recent studies showed that receptor activator of nuclear factor κB (RANK) was expressed not only in osteoclast precursors but also in tumor cells. Therefore, we examined whether RANK ligand (RANKL)/RANK signaling regulates bone invasion by OSCC cells in vivo and in vitro. We first injected human OSCC B88 cells into the masseter region of nude mice. Mice were treated for 3 weeks with osteoprotegerin (OPG), the decoy receptor for RANKL. Treatment with OPG decreased bone invasion by B88 cells, reduced the number of osteoclasts and increased B88 cell apoptosis. However, OPG did not affect apoptosis and proliferation in B88 cells in vitro, suggesting that the effects of OPG on apoptosis in B88 cells are restricted in a bone environment. RANK was expressed in the B88 cells and in OSCC cells from patients. RANKL induced NF-κB activation and extracellular signal-regulated kinase phosphorylation in B88 cells and enhanced B88 cell migration in a modified chemotaxis chamber equipped with a gelatin-coated filter. OPG inhibited RANKL-induced NF-κB activation, extracellular signal-regulated kinase phosphorylation and cell migration. Our data clearly indicate that RANKL/RANK inhibition suppresses bone invasion by inhibiting osteoclastogenesis and cancer cell migration and by inducing apoptosis of cancer cells via indirect anticancer action in vivo.

UR - http://www.scopus.com/inward/record.url?scp=80755168375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755168375&partnerID=8YFLogxK

U2 - 10.1093/carcin/bgr198

DO - 10.1093/carcin/bgr198

M3 - Article

C2 - 21890459

AN - SCOPUS:80755168375

VL - 32

SP - 1634

EP - 1640

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 11

ER -